Puromycin aminonucleoside (58-60-6) is the nucleoside moiety of puromycin (Cat.# 10-2100) which does not inhibit protein synthesis or induce apoptosis.1?It acts as a glomerular epithelial cell toxin2 and as such is a useful tool for producing animal models of nephropathy3,4, or puromycin aminonucleoside nephrosis (1-2.5 mg/100g rat body weight)5. Active in vivo.
Puromycin aminonucleoside is a semi-synthetic derivative of puromycin which lacks the methoxyphenylalanyl moiety. Puromycin aminonucleoside is the key intermediate in the synthesis of semi-synthetic analogues of puromycin. It does not inhibit protein synthesis or induce apoptosis, but exhibits antitumour properties. Puromycin aminonucleoside-induced nephrosis is a well-described model of human idiopathic nephrotic syndrome, suppressing integrin expression in cultured glomerular epithelial cells.
Puromycin Aminonucleoside is an aminonucleoside portion of the antibiotic puromycin.
ChEBI: Puromycin derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring.
An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx,.
1) Chow et al. (1995), Reevaluation of the role of de novo protein synthesis in rat thymocyte apoptosis; Exp. Cell Res., 216 149
2) Krishnamurti et al. (2001), Puromycin aminonucleoside suppresses integrin expression in cultured glomerular epithelial cells; J. Am. Soc. Nephrol., 12 758
3) Egashira et al. (2006), Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis; Int. J. Vitam. Nutr. Res., 76 28
4) Hagiwara et al. (2006), Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis; Kidney Int., 69 1146
5) Lowenborg et al. (2000), Glomerular function and morphology in puromycin aminonucleoside nephropathy in rats; Nephrol. Dial. Transplant, 15 1547
